Discovering methods or molecules able to decrease CXCL13 secretion could expand therapeutic options in demyelinating diseases, as tissue samples from patients with MS and its murine model show increased CXCL13 synthesis in glial cells [97,103,104]. This evidence concerns the gene CXCL13 and myeloid sarcoma.